PANZYGA (Octapharma Australia Pty Ltd)

PANZYGA (solution for intravenous infusion) is indicated for:

Replacement therapy in:

• Primary immunodeficiency diseases
• Myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent bacterial infections
• Symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment

Immunomodulation in:

• Idiopathic thrombocytopenic purpura (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count
• Guillain Barré syndrome
• Kawasaki disease